Clinical Trial Update: DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) [Phase 2]

View source ↗

Summary

Phase 2 trial update for DS-8201a (trastuzumab deruxtecan) in HER2-expressing colorectal cancer (DESTINY-CRC01) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Neoplasm

Drugs mentioned

• DS-8201a (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Colorectal Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2021-08-24